Elan sells remaining shares to Alkermes; Spectrum stock spikes;

 @FierceBiotech: Juventas snaps up business development veteran, more in this week's roundup of hirings and firings in biotech, pharma. More | Follow @FierceBiotech

@JohnCFierce: Odana is one of Merck's top PhIII drugs, and like suvorexant may not sell well against generics. Where's the breakthrough strategy? More | Follow @JohnCFierce

@RyanMFierce: Gilead hungers for more cancer drug deals. But Ariad? Story | Follow @RyanMFierce

> Elan ($ELN) has agreed to sell all of its remaining 7,750,000 ordinary shares of Alkermes through Jefferies & Company. Elan sold its Elan Drug Technologies (EDT) formulation and manufacturing business to Alkermes in a cash and shares deal valued at $960 million in 2011. Release

> Spectrum Pharmaceuticals' ($SPPI) stock jumped Thursday after the company said it regained rights from Allergan ($AGN) to market its bladder cancer drug apaziquone and is making progress with the FDA to consider the drug's approval. Story

> Researchers in China think a protein derived from pigs has potential to treat dementia patients. Story

Pharma News

@FiercePharma: Genzyme's $176K Kynamro price undercuts its $250K-plus rival. But rivalry in orphan drugs isn't the usual. Article | Follow @FiercePharma

@EricPFierce: Medicare refiguring how it will pay for dialysis drugs. It is part of the new payer world. More | Follow @EricPFierce

> U.K. gatekeepers shut out AZ and BMS' new diabetes drug. Story

> Merck has to trim outlook as pipeline poops out. Article

> Pfizer's Zoetis spinoff outshines drug biz, at least for a day. More

> OTC plant bites Novartis' reputation again. Report

Medical Device News

 @FierceMedDev: New special report: Top diagnostics VC investments of 2012. More | Follow @FierceMedDev

 @MarkHFierce: Philips Healthcare had a solid Q4--the overall company, less so. More | Follow @MarkHFierce

 @DamianFierce: Add Smith & Nephew to the list of companies cutting jobs and blaming the 2.3% medical device tax. Report | Follow @DamianFierce

> GE pursues 'corrective action' for more parts used in two infant warmers. Article

> Ivantis hauls in $27M for tiny eye stent. Story

> MITA: CMS should weigh Dx endpoints for beta amyloid PET imaging coverage. Item

And Finally... Could the study of folkloric beasts have a place in mainstream science? Story

Suggested Articles

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.